Exhibit F

Infringement of Claim 1 of U.S. Patent Number 8,687,879 by Qmetrics

CLAIM LANGUAGE	Infringing Application
1. A non-transitory computer program product for automating the expert quantification of image data comprising: a computer-readable medium encoded with computer readable instructions executable by one or more computer processors to quantify image sets comprising a locked evolving algorithm, wherein said locked evolving algorithm is generated by:	**Announcing DiscernAI™…Improving Clinical Trials by SEEING MORE** Qmetrics can uncover important data insights by *seeing more*. Whether it is automatically segmenting hard-to-detect features of the knee or leveraging machine learning to detect early mild cognitive impairment in the brain, Qmetrics expertise is unique in the industry. Now, Qmetrics is pleased to announce its new service, **DiscernAI™**. *DiscernAI* improves data analyses through the use of artificial intelligence (AI) and machine learning (ML). *DiscernAI*'s data mining platform includes proprietary software and a growing catalogue of machine learning-based "signatures." The *DiscernAI* platform has been developed over many years by Qmetrics' imaging and data science experts. **By using *DiscernAI* to *see more*, Qmetrics brings unique value to biopharma and CROs, allowing the discovery of unique subject characteristics using advanced machine learning techniques on clinical data and images to improve clinical trials.** ***DiscernAI Signatures*** are a set of quantified clinical, genetic, and post-processed imaging features that identify unique patient characteristics, disease states, or treatment responses. These *DiscernAI Signatures* have been previously discovered and validated, and can be applied to existing data without additional machine learning. http://web.qmetricstech.com/qmetrics/discernai/ Qmetrics imaging technology ("Infringing Product") is a computer program product for generating image analysis.

Exhibit F

obtaining a product algorithm for analysis of a first set of image data wherein said product algorithm is configured to recognize at least one entity within said first set of image data via a training mode that utilizes iterative input to an evolving algorithm obtained from at least one first user, wherein said training mode comprises:	**Announcing DiscernAI™…Improving Clinical Trials by SEEING MORE** Qmetrics can uncover important data insights by **seeing more**. Whether it is automatically segmenting hard-to-detect features of the knee or leveraging machine learning to detect early mild cognitive impairment in the brain, Qmetrics expertise is unique in the industry. Now, Qmetrics is pleased to announce its new service, **DiscernAI™**. *DiscernAI* improves data analyses through the use of artificial intelligence (AI) and machine learning (ML). *DiscernAI*'s data mining platform includes proprietary software and a growing catalogue of machine learning-based "signatures." The *DiscernAI* platform has been developed over many years by Qmetrics' imaging and data science experts. By using *DiscernAI* to **see more**, Qmetrics brings unique value to biopharma and CROs, allowing the discovery of unique subject characteristics using advanced machine learning techniques on clinical data and images to improve clinical trials. **DiscernAI Signatures** are a set of quantified clinical, genetic, and post-processed imaging features that identify unique patient characteristics, disease states, or treatment responses. These *DiscernAI Signatures* have been previously discovered and validated, and can be applied to existing data without additional machine learning. http://web.qmetricstech.com/qmetrics/discernai/ The Infringing Product generates an algorithm based on user manual annotation of objects of interest thereby training the algorithm.

Exhibit F

presenting a first set of said at least one entity to said user for feedback as to the accuracy of said first set of identified entities; obtaining said feedback from said user; executing said evolving algorithm using said feedback;	**Announcing DiscernAI™…Improving Clinical Trials by SEEING MORE** Qmetrics can uncover important data insights by *seeing more*. Whether it is automatically segmenting hard-to-detect features of the knee or leveraging machine learning to detect early mild cognitive impairment in the brain, Qmetrics expertise is unique in the industry. Now, Qmetrics is pleased to announce its new service, **DiscernAI™**. *DiscernAI* improves data analyses through the use of artificial intelligence (AI) and machine learning (ML). *DiscernAI*'s data mining platform includes proprietary software and a growing catalogue of machine learning-based "signatures." The *DiscernAI* platform has been developed over many years by Qmetrics' imaging and data science experts. By using *DiscernAI* to *see more*, Qmetrics brings unique value to biopharma and CROs, allowing the discovery of unique subject characteristics using advanced machine learning techniques on clinical data and images to improve clinical trials. **DiscernAI Signatures** are a set of quantified clinical, genetic, and post-processed imaging features that identify unique patient characteristics, disease states, or treatment responses. These *DiscernAI Signatures* have been previously discovered and validated, and can be applied to existing data without additional machine learning. http://web.qmetricstech.com/qmetrics/discernai/ The Infringing Product generates an algorithm based on user manual annotation of objects of interest thereby training the algorithm.

Page **3** of **4**

Exhibit F

presenting a second set of said at least one entity to said user for feedback as to the accuracy of said second set of identified entities; obtaining approval from said user about said second set of entities; storing said evolving algorithm as a product algorithm; and storing said product algorithm for subsequent usage on said image set.	**Announcing DiscernAI™…Improving Clinical Trials by SEEING MORE** Qmetrics can uncover important data insights by *seeing more*. Whether it is automatically segmenting hard-to-detect features of the knee or leveraging machine learning to detect early mild cognitive impairment in the brain, Qmetrics expertise is unique in the industry. Now, Qmetrics is pleased to announce its new service, **DiscernAI™**. *DiscernAI* improves data analyses through the use of artificial intelligence (AI) and machine learning (ML). *DiscernAI*'s data mining platform includes proprietary software and a growing catalogue of machine learning-based "signatures." The *DiscernAI* platform has been developed over many years by Qmetrics' imaging and data science experts. By using *DiscernAI* to *see more*, Qmetrics brings unique value to biopharma and CROs, allowing the discovery of unique subject characteristics using advanced machine learning techniques on clinical data and images to improve clinical trials. **DiscernAI Signatures** are a set of quantified clinical, genetic, and post-processed imaging features that identify unique patient characteristics, disease states, or treatment responses. These *DiscernAI Signatures* have been previously discovered and validated, and can be applied to existing data without additional machine learning. http://web.qmetricstech.com/qmetrics/discernai/ The Infringing product utilizes the deep learning training i.e more than one set of data entity to the user for the feedback and training the algorithm. **Announcing DiscernAI™…Improving Clinical Trials by SEEING MORE** Qmetrics can uncover important data insights by *seeing more*. Whether it is automatically segmenting hard-to-detect features of the knee or leveraging machine learning to detect early mild cognitive impairment in the brain, Qmetrics expertise is unique in the industry. Now, Qmetrics is pleased to announce its new service, **DiscernAI™**. *DiscernAI* improves data analyses through the use of artificial intelligence (AI) and machine learning (ML). *DiscernAI*'s data mining platform includes proprietary software and a growing catalogue of machine learning-based "signatures." The *DiscernAI* platform has been developed over many years by Qmetrics' imaging and data science experts. By using *DiscernAI* to *see more*, Qmetrics brings unique value to biopharma and CROs, allowing the discovery of unique subject characteristics using advanced machine learning techniques on clinical data and images to improve clinical trials. **DiscernAI Signatures** are a set of quantified clinical, genetic, and post-processed imaging features that identify unique patient characteristics, disease states, or treatment responses. These *DiscernAI Signatures* have been previously discovered and validated, and can be applied to existing data without additional machine learning. http://web.qmetricstech.com/qmetrics/discernai/ The Infringing Product stores the evolving algorithm and runs the stored algorithm on all the data to automatically classify additional image of similar type/requirement.